Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) EBT: 2018-2025

Historic EBT for Neurogene (NGNE) over the last 4 years, with Sep 2025 value amounting to -$21.1 million.

  • Neurogene's EBT fell 3.65% to -$21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.8 million, marking a year-over-year decrease of 23.93%. This contributed to the annual value of -$75.7 million for FY2024, which is 43.76% down from last year.
  • Latest data reveals that Neurogene reported EBT of -$21.1 million as of Q3 2025, which was up 9.15% from -$23.2 million recorded in Q2 2025.
  • Neurogene's 5-year EBT high stood at -$11.9 million for Q2 2023, and its period low was -$23.2 million during Q2 2025.
  • Over the past 3 years, Neurogene's median EBT value was -$18.6 million (recorded in 2024), while the average stood at -$17.8 million.
  • Data for Neurogene's EBT shows a maximum YoY slumped of 57.14% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Neurogene's EBT stood at -$14.0 million in 2023, then plummeted by 40.71% to -$19.7 million in 2024, then declined by 3.65% to -$21.1 million in 2025.
  • Its EBT was -$21.1 million in Q3 2025, compared to -$23.2 million in Q2 2025 and -$22.8 million in Q1 2025.